291 related articles for article (PubMed ID: 33045661)
21. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
Lamparter CL; Winn LM
Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
[TBL] [Abstract][Full Text] [Related]
22. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
23. Characterization of novel inhibitors of histone acetyltransferases.
Eliseeva ED; Valkov V; Jung M; Jung MO
Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
[TBL] [Abstract][Full Text] [Related]
24. Curcumin is an inhibitor of p300 histone acetylatransferase.
Marcu MG; Jung YJ; Lee S; Chung EJ; Lee MJ; Trepel J; Neckers L
Med Chem; 2006 Mar; 2(2):169-74. PubMed ID: 16787365
[TBL] [Abstract][Full Text] [Related]
25. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function.
Wang L; Tang Y; Cole PA; Marmorstein R
Curr Opin Struct Biol; 2008 Dec; 18(6):741-7. PubMed ID: 18845255
[TBL] [Abstract][Full Text] [Related]
26. Another One (of the "Undruggable" Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP.
Kodadek T
Biochemistry; 2018 Feb; 57(6):899-900. PubMed ID: 29244478
[No Abstract] [Full Text] [Related]
27. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
29. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
30. The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3.
Zhang Y; Xue Y; Shi J; Ahn J; Mi W; Ali M; Wang X; Klein BJ; Wen H; Li W; Shi X; Kutateladze TG
Nat Struct Mol Biol; 2018 Sep; 25(9):841-849. PubMed ID: 30150647
[TBL] [Abstract][Full Text] [Related]
31. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
32. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
Sbardella G; Castellano S; Vicidomini C; Rotili D; Nebbioso A; Miceli M; Altucci L; Mai A
Bioorg Med Chem Lett; 2008 May; 18(9):2788-92. PubMed ID: 18434144
[TBL] [Abstract][Full Text] [Related]
33. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
35. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
36. Azide-alkyne cycloaddition affording enzymatically tunable bisubstrate based inhibitors of histone acetyltransferase PCAF.
van Ameijde J; Zwiebel AP; Ruijtenbeek R; Liskamp RM
Bioorg Med Chem Lett; 2014 Jan; 24(1):113-6. PubMed ID: 24345448
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of CBP/p300 HAT.
Sarli V; Giannis A
Chem Biol; 2007 Jun; 14(6):605-6. PubMed ID: 17584607
[TBL] [Abstract][Full Text] [Related]
39. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases.
Mai A; Rotili D; Tarantino D; Nebbioso A; Castellano S; Sbardella G; Tini M; Altucci L
Bioorg Med Chem Lett; 2009 Feb; 19(4):1132-5. PubMed ID: 19144517
[TBL] [Abstract][Full Text] [Related]
40. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
